CFO at Twist Bioscience (NASDAQ: TWST) sells 4,000 shares

Rhea-AI Filing Summary

Twist Bioscience Corp Chief Financial Officer Adam Laponis sold 4,000 shares of Common Stock in an open-market transaction. The sale occurred at a price of $60.00 per share on April 17, 2026. After this transaction, he directly holds 118,694 shares of Twist Bioscience common stock.

The sale was carried out under a pre-arranged Rule 10b5-1 trading plan that Laponis previously adopted on May 8, 2025, indicating the transaction was scheduled in advance rather than timed discretionarily.

Insider Trade Summary 10b5-1

Net Seller: 4,000 shares ($240,000)

Net Sell 1 txn

Insider Laponis Adam

Role Chief Financial Officer

Sold 4,000 shs ($240K)

Type	Security	Shares	Price	Value
Sale	Common Stock	4,000	$60.00	$240K

Holdings After Transaction: Common Stock — 118,694 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares sold: 4,000 shares Sale price: $60.00 per share Shares held after sale: 118,694 shares +2 more

5 metrics

Shares sold 4,000 shares Open-market sale of Common Stock on April 17, 2026

Sale price $60.00 per share Price received for the 4,000 shares sold

Shares held after sale 118,694 shares Direct Common Stock holdings following the transaction

Net buy/sell shares -4,000 shares Net effect of reported transactions in this Form 4

Transactions classified as sales 1 transaction Single non-derivative open-market sale reported

Key Terms

Rule 10b5-1 trading plan, open-market sale, Form 4, Common Stock, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"The transaction reported on this Form 4 is effected pursuant to a Rule 10b5-1 trading plan previously adopted..."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market sale financial

"transaction_action: "open-market sale" for 4,000 shares of Common Stock"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 regulatory

"The transaction reported on this Form 4 is effected pursuant to a Rule 10b5-1 trading plan..."

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Common Stock financial

"security_title: "Common Stock" with 4,000.0000 shares sold at $60.0000"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Chief Financial Officer financial

"Reporting person Adam Laponis serves as Chief Financial Officer of Twist Bioscience Corp"

A Chief Financial Officer (CFO) is the person in charge of a company's money and financial planning. They decide how to spend, save, and invest funds to help the company grow and stay stable. Their role is important because good financial decisions keep the company healthy and successful.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Laponis Adam

(Last) (First) (Middle)

C/O TWIST BIOSCIENCE CORPORATION

681 GATEWAY BLVD

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Twist Bioscience Corp [ TWST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/17/2026		S		4,000(1)	D	$60	118,694	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transaction reported on this Form 4 is effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 8, 2025.

Remarks:

	/s/ Kendra Fox, as Attorney-in-Fact for Adam Laponis	04/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Twist Bioscience (TWST) report in this Form 4?

Twist Bioscience reported that CFO Adam Laponis sold 4,000 shares of Common Stock. The open-market sale took place on April 17, 2026 at $60.00 per share, reducing but not eliminating his direct shareholdings in the company.

Was the Twist Bioscience (TWST) CFO sale made under a Rule 10b5-1 trading plan?

Yes. The filing states the transaction was effected under a Rule 10b5-1 trading plan. This plan was previously adopted by the reporting person on May 8, 2025, indicating the sale was pre-scheduled rather than initiated on a purely discretionary basis.

How many Twist Bioscience (TWST) shares does the CFO hold after this transaction?

Following the reported sale, CFO Adam Laponis directly holds 118,694 shares of Twist Bioscience Common Stock. This post-transaction balance is disclosed in the filing and reflects his remaining direct equity position after selling 4,000 shares at $60.00 per share.

What price did the Twist Bioscience (TWST) CFO receive for the shares sold?

The CFO’s reported open-market sale was executed at $60.00 per share. In total, 4,000 shares of Twist Bioscience Common Stock were sold at this price, as disclosed in the Form 4, representing a single non-derivative transaction on April 17, 2026.

Does this Twist Bioscience (TWST) Form 4 include any option exercises or derivative transactions?

No. The filing reports only one non-derivative transaction: an open-market sale of Common Stock. The derivative summary section is empty, indicating no option exercises, conversions, or other derivative-related transactions were reported in this particular Form 4.

Is the Twist Bioscience (TWST) CFO’s reported ownership direct or through an entity?

The Form 4 identifies the CFO’s ownership as direct. The transaction is coded with direct ownership, and there is no footnote indicating that the shares are held through a separate trust, partnership, or other indirect holding entity for this specific transaction.